OneMedNet Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OneMedNet Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $643.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.02M | Apr 15, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $643.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.02M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.15M | Nov 5, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($503.0K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($281.0K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($129.0K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($360.0K) | Nov 5, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.80M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($10.13M) | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | ($2.06M) | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | ($3.59M) | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | ($2.11M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($33.78M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($30.45M) | Nov 5, 2024 |
| FY2022 | Dec 31, 2021 | $5.14M | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.67M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($9.61M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($6.85M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($7.72M) | Nov 5, 2024 |
| FY2022 | Dec 31, 2021 | ($585.4K) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.52M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.47M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.07M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.59M | Nov 5, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.50M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($6.95M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($4.79M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($4.70M) | Nov 5, 2024 |
| FY2022 | Dec 31, 2021 | ($378.5K) | Mar 31, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $51.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $44.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $58.0K | Nov 5, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.73M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $464.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.29M | Nov 5, 2024 |
| FY2022 | Dec 31, 2021 | $117.86M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.12M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $19.68M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $13.91M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $27.65M | Nov 5, 2024 |
| FY2022 | Dec 31, 2021 | $9.17M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.97M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($15.95M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | ($13.44M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | ($26.36M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | ($7.05M) | Nov 5, 2024 |
| FY2022 | Feb 7, 2021 | $0 | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($104.37M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($101.57M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($91.44M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($57.66M) | Nov 5, 2024 |
| FY2022 | Dec 31, 2021 | ($8.61M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $585.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $172.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $47.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $271.0K | Nov 5, 2024 |
| FY2022 | Dec 31, 2021 | $453.2K | Mar 31, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2024 | $2.32M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $465.0K | Apr 15, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | (4) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Nov 5, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | (4) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Nov 5, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.98M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 27.99M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 23.57M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 4.03M | Nov 5, 2024 |